J&J's blockbuster hopefuls get EMA recommendation

Johnson & Johnson ($JNJ) saw its stable of new drugs strengthened at last week's meeting of European regulators. The European Medicines Agency's drug-approval panel backed its new prostate cancer drug Zytiga and its new hepatitis C treatment Incivo. As Bloomberg notes, both are presumed blockbusters that could help give J&J sales a multibillion-dollar boost.

Zytiga won approval in the U.S. earlier this year, as did Incivo, which is sold in that market by Vertex Pharmaceuticals ($VRTX) under the brand name Incivek. Citigroup's Matthew Dodds has tagged peak sales of Zytiga at $1.1 billion by 2015, while Incivo could hit $1.4 billion by the same year, Bloomberg notes.

The final European approval will have to come from the European Commission, but J&J is expected to be able to launch the drugs on the continent by the end of this year. In fact, J&J's Janssen Pharmaceutical is raring to go; Incivo medical leader Jim Witek told Bloomberg that Incivo could be on the market within days of the EC's blessing.

- read the Bloomberg story

ALSO: Johnson & Johnson (JNJ)'s Simponi, a treatment for rheumatoid arthritis, wasn't approved by U.S. regulators as a way to inhibit the progression of damage from the disease. Report

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.